Doximity, Inc. (DOCS)

NYSE:DOCS

DOCS

Doximity

RESEARCH TOOLSreports

Want to see DOCS full AI Analyst Report?

Doximity (DOCS) Stock Forecast & Price Target

999 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DOCS Analyst Ratings

Moderate Buy

9 Buy

12 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Doximity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DOCS Stock 12 Month Forecast

Average Price Target

$26.78

▲(8.37% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $26.78 with a high forecast of $47.00 and a low forecast of $18.00. The average price target represents a 8.37% change from the last price of $24.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","44":"$44","71":"$71","30.5":"$30.5","57.5":"$57.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.777777777777775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,30.5,44,57.5,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.98,26.673846153846153,28.36769230769231,30.06153846153846,31.755384615384614,33.449230769230766,35.14307692307692,36.83692307692308,38.53076923076923,40.22461538461538,41.91846153846154,43.612307692307695,45.30615384615385,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.98,25.1182905982906,25.256581196581198,25.394871794871793,25.533162393162392,25.67145299145299,25.80974358974359,25.948034188034185,26.086324786324784,26.224615384615383,26.362905982905982,26.501196581196577,26.639487179487176,{"y":26.777777777777775,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.98,24.443076923076923,23.906153846153845,23.369230769230768,22.832307692307694,22.295384615384616,21.75846153846154,21.22153846153846,20.684615384615384,20.14769230769231,19.61076923076923,19.073846153846155,18.536923076923078,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.38,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.93,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$47.00

Average Price Target$26.78

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Alexei Gogolev

J.P. Morgan

$33→$28

Hold

13.31%

Upside

Reiterated

05/18/26

Doximity (DOCS) Gets a Hold from J.P. Morgan

Jailendra Singh

Truist Financial

$19

Hold

-23.11%

Downside

Reiterated

05/18/26

Doximity (DOCS) Receives a Hold from Truist Financial

Michael Cherny

Leerink Partners

$31→$25

Buy

1.17%

Upside

Assigned

05/15/26

Doximity price target lowered to $25 from $31 at LeerinkDoximity price target lowered to $25 from $31 at Leerink

David Roman

Goldman Sachs

$28→$24

Hold

-2.87%

Downside

Assigned

05/15/26

Doximity price target lowered to $24 from $28 at Goldman SachsDoximity price target lowered to $24 from $28 at Goldman Sachs

Richard Close

Canaccord Genuity

$34→$30

Buy

21.41%

Upside

Reiterated

05/14/26

Doximity price target lowered to $30 from $34 at CanaccordDoximity price target lowered to $30 from $34 at Canaccord

Brian Tanquilut

Jefferies

$51→$19

Hold

-23.11%

Downside

Downgraded

05/14/26

Doximity downgraded to Hold from Buy at JefferiesDoximity downgraded to Hold from Buy at Jefferies

Craig Hettenbach

Morgan Stanley

$49→$35

Buy

41.64%

Upside

Assigned

05/14/26

Doximity price target lowered to $35 from $49 at Morgan StanleyDoximity price target lowered to $35 from $49 at Morgan Stanley

Glen Santangelo

Barclays

$20

Hold

-19.06%

Downside

Downgraded

05/14/26

Doximity downgraded to Equal Weight from Overweight at BarclaysDoximity downgraded to Equal Weight from Overweight at Barclays

Vikram Kesavabhotla

Robert W. Baird

$40→$18

Hold

-27.15%

Downside

Downgraded

05/14/26

Doximity downgraded to Neutral from Outperform at BairdDoximity downgraded to Neutral from Outperform at Baird

Steven Valiquette

Mizuho Securities

$34→$26

Hold

5.22%

Upside

Reiterated

05/14/26

Doximity price target lowered to $26 from $34 at MizuhoDoximity price target lowered to $26 from $34 at Mizuho

Ryan Daniels

William Blair

―

Buy

―

Reiterated

05/14/26

Doximity: Buy Rating Backed by Solid Q4 Results, Cyclical Pharma Headwinds, and Long-Term AI Growth Strategy

Ryan Halsted

RBC Capital

$44→$28

Buy

13.31%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (NASDAQ: ORKA), GH Research (NASDAQ: GHRS) and Doximity (NYSE: DOCS)

Jessica Tassan

Piper Sandler

$42

Buy

69.97%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Doximity (NYSE: DOCS)

Stan Berenshteyn

Wells Fargo

$32→$18

Hold

-27.15%

Downside

Downgraded

05/14/26

Doximity downgraded to Equal Weight from Overweight at Wells FargoDoximity downgraded to Equal Weight from Overweight at Wells Fargo

Sean Dodge

BMO Capital

$25→$20

Hold

-19.06%

Downside

Reiterated

05/14/26

Doximity price target lowered to $20 from $25 at BMO CapitalDoximity price target lowered to $20 from $25 at BMO Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Alexei Gogolev

J.P. Morgan

$33→$28

Hold

13.31%

Upside

Reiterated

05/18/26

Doximity (DOCS) Gets a Hold from J.P. Morgan

Jailendra Singh

Truist Financial

$19

Hold

-23.11%

Downside

Reiterated

05/18/26

Doximity (DOCS) Receives a Hold from Truist Financial

Michael Cherny

Leerink Partners

$31→$25

Buy

1.17%

Upside

Assigned

05/15/26

Doximity price target lowered to $25 from $31 at LeerinkDoximity price target lowered to $25 from $31 at Leerink

David Roman

Goldman Sachs

$28→$24

Hold

-2.87%

Downside

Assigned

05/15/26

Doximity price target lowered to $24 from $28 at Goldman SachsDoximity price target lowered to $24 from $28 at Goldman Sachs

Richard Close

Canaccord Genuity

$34→$30

Buy

21.41%

Upside

Reiterated

05/14/26

Doximity price target lowered to $30 from $34 at CanaccordDoximity price target lowered to $30 from $34 at Canaccord

Brian Tanquilut

Jefferies

$51→$19

Hold

-23.11%

Downside

Downgraded

05/14/26

Doximity downgraded to Hold from Buy at JefferiesDoximity downgraded to Hold from Buy at Jefferies

Craig Hettenbach

Morgan Stanley

$49→$35

Buy

41.64%

Upside

Assigned

05/14/26

Doximity price target lowered to $35 from $49 at Morgan StanleyDoximity price target lowered to $35 from $49 at Morgan Stanley

Glen Santangelo

Barclays

$20

Hold

-19.06%

Downside

Downgraded

05/14/26

Doximity downgraded to Equal Weight from Overweight at BarclaysDoximity downgraded to Equal Weight from Overweight at Barclays

Vikram Kesavabhotla

Robert W. Baird

$40→$18

Hold

-27.15%

Downside

Downgraded

05/14/26

Doximity downgraded to Neutral from Outperform at BairdDoximity downgraded to Neutral from Outperform at Baird

Steven Valiquette

Mizuho Securities

$34→$26

Hold

5.22%

Upside

Reiterated

05/14/26

Doximity price target lowered to $26 from $34 at MizuhoDoximity price target lowered to $26 from $34 at Mizuho

Ryan Daniels

William Blair

―

Buy

―

Reiterated

05/14/26

Doximity: Buy Rating Backed by Solid Q4 Results, Cyclical Pharma Headwinds, and Long-Term AI Growth Strategy

Ryan Halsted

RBC Capital

$44→$28

Buy

13.31%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (NASDAQ: ORKA), GH Research (NASDAQ: GHRS) and Doximity (NYSE: DOCS)

Jessica Tassan

Piper Sandler

$42

Buy

69.97%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Doximity (NYSE: DOCS)

Stan Berenshteyn

Wells Fargo

$32→$18

Hold

-27.15%

Downside

Downgraded

05/14/26

Doximity downgraded to Equal Weight from Overweight at Wells FargoDoximity downgraded to Equal Weight from Overweight at Wells Fargo

Sean Dodge

BMO Capital

$25→$20

Hold

-19.06%

Downside

Reiterated

05/14/26

Doximity price target lowered to $20 from $25 at BMO CapitalDoximity price target lowered to $20 from $25 at BMO Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Doximity

3 Months

Richard CloseCanaccord Genuity

Success Rate

9/17 ratings generated profit

Average Return

+2.59%

Copying Richard Close's trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +2.59% per trade.

1 Year

Jessica TassanPiper Sandler

Success Rate

4/8 ratings generated profit

Average Return

-11.04%

Copying Jessica Tassan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -11.04% per trade.

2 Years

Richard CloseCanaccord Genuity

Success Rate

10/17 ratings generated profit

Average Return

+34.43%

Copying Richard Close's trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +34.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DOCS Analyst Recommendation Trends

Rating

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DOCS has received 17 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. DOCS average Analyst price target in the past 3 months is 26.78.

Each month's total comprises the sum of three months' worth of ratings.

DOCS Financial Forecast

DOCS Earnings Forecast

Next quarter’s earnings estimate for DOCS is $0.30 with a range of $0.28 to $0.33. The previous quarter’s EPS was $0.26. DOCS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DOCS has Performed in-line its overall industry.

DOCS Sales Forecast

Next quarter’s sales forecast for DOCS is $151.54M with a range of $151.00M to $152.00M. The previous quarter’s sales results were $145.37M. DOCS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DOCS has Performed in-line its overall industry.

DOCS Stock Forecast FAQ

What is DOCS’s average 12-month price target, according to analysts?

Based on analyst ratings, Doximity, Inc.’s 12-month average price target is 26.78.

What is DOCS’s upside potential, based on the analysts’ average price target?

Doximity, Inc. has 8.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DOCS a Buy, Sell or Hold?

Doximity, Inc. has a consensus rating of Moderate Buy which is based on 9 buy ratings, 12 hold ratings and 0 sell ratings.

What is Doximity, Inc.’s price target?

The average price target for Doximity, Inc. is 26.78. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $47.00 ,the lowest forecast is $18.00. The average price target represents 8.37% Increase from the current price of $24.71.

What do analysts say about Doximity, Inc.?

Doximity, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of DOCS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Doximity (DOCS) Stock Forecast & Price Target

DOCS Analyst Ratings

DOCS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Doximity

DOCS Analyst Recommendation Trends

DOCS Financial Forecast

DOCS Earnings Forecast

DOCS Sales Forecast

DOCS Stock Forecast FAQ

Detailed List of Analyst Forecasts